Skip to main content

Human Clinical Trial of Ebola Vaccine Started

  • Published: 2014-11-01 (Revised/Updated 2018-01-25) : *Press Release by NIH/National Institute of Allergy and Infectious Diseases : Contact: Kathy Stover -
  • Synopsis: Researchers at NIAID are conducting early phase trial to evaluate VSV-ZEBOV Ebola virus vaccine.

Quote: "Scientists at Canada's National Microbiology Lab developed this Ebola vaccine, following years of hard work."

Main Document

Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center.

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are conducting the early phase trial to evaluate the vaccine, called VSV-ZEBOV, for safety and its ability to generate an immune system response in healthy adults who are given two intramuscular doses, called a prime-boost strategy. The Walter Reed Army Institute of Research (WRAIR) is simultaneously testing the vaccine candidate as a single dose at its Clinical Trials Center.

"The need for a vaccine to protect against Ebola infection is urgent," said NIAID Director Anthony S. Fauci, M.D. "NIH welcomes the opportunity to collaborate with the U.S. Department of Defense to conduct human clinical tests of another promising - and hopefully, successful - Ebola vaccine candidate."

NIAID researchers include principal investigator Richard T. Davey, M.D., and co-investigator John Beigel, M.D., of NIAID's Division of Intramural Research.

Early human testing of another investigational Ebola vaccine co-developed by NIAID and GlaxoSmithKline (GSK) began in early September. Initial data on safety and immunogenicity (the capacity to generate an immune response) from clinical trials of the NIAID/GSK Ebola vaccine are expected by the end of 2014.

The VSV-ZEBOV vaccine candidate was developed by researchers at the Public Health Agency of Canada's National Microbiology Laboratory. It has been licensed to NewLink Genetics Corp through its wholly owned subsidiary Bio-Protection Systems, both based in Ames, Iowa.

"Canada has long been a world leader in Ebola research and innovation. Scientists at Canada's National Microbiology Lab developed this Ebola vaccine, following years of hard work. We hope the clinical trial at the National Institutes of Health proves to be safe and effective, so that the Canadian Ebola vaccine can be used as a global resource to help save lives and end this complex outbreak in West Africa," said Canada's Minister of Health Rona Ambrose.

"We are pleased to recognize the extraordinary work of our partners to move the VSV-ZEBOV vaccine candidate from preclinical development to clinical testing in a matter of weeks rather than years. This level of support has been and will continue to be a critical asset in the ongoing process of evaluating and potentially bringing this investigational product to broader use in the fight against Ebola virus," said Charles Link, M.D., chief scientific officer and CEO, NewLink Genetics.

VSV-Zebov is based in part on a genetically engineered version of vesicular stomatitis virus (VSV), which primarily affects rodents, cattle, swine and horses. Human VSV infections are rare and generally produce three to four days of mild illness. In the VSV-ZEBOV investigational vaccine, the gene for the outer protein of the vesicular stomatitis virus has been replaced with a segment of the gene for the outer protein of the Zaire Ebola virus species. The investigational VSV-ZEBOV vaccine cannot cause a vaccinated individual to become infected with Ebola.

The NIH Phase 1 clinical trial of the VSV-ZEBOV vaccine candidate will enroll 39 healthy adults aged 18 to 65 years. Participants will be randomly assigned to one of three groups with 13 participants each. In each group, 10 participants will receive the investigational VSV-ZEBOV vaccine; three will receive a placebo. Each of the three groups will receive a different, escalating dose of the investigational vaccine, with the first group enrolled receiving the lowest dose and the third group enrolled receiving the highest dose. Study participants will receive an injection of the VSV-ZEBOV vaccine or placebo at their first scheduled visit and again, at the same dosage level, 28 days later.

Enrollment at each dosing level is staggered, so interim safety assessments of vaccinated individuals can be conducted before moving to the next dosing level. All study participants will be seen and evaluated by clinical staff 11 times over one year.

While NIAID tests the VSV-ZEBOV vaccine candidate as a prime-boost strategy, WRAIR is evaluating the investigational vaccine as a single injection. This is being done to evaluate in real time the safety profile of the investigational vaccine when provided at different dosages and compare the immune responses induced by one injection versus two injections. Initial safety and immune response data on the VSV-ZEBOV vaccine are expected by the end of 2014.

More information about the NIAID clinical trial of the investigational VSV-ZEBOV Ebola vaccine is available at using the identifier NCT02257840.


• Have your say! Add your comment or discuss this article on our FaceBook Page.

Similar Topics

1 : South Africa Ready to Deal with Ebola : Brand South Africa.
2 : Treating Ebola in the US - First Hemopurifier Shipment : Aethlon Medical, Inc..
3 : Study Predicts Likely Ebola Cases Entering UK and US Through Airport Screening : University of Liverpool.
4 : RNs to Join Global Ebola Awareness Day Actions with Vigils, Rallies and Strikes : California Nurses Association.
5 : Ebola Education Module and Safety Poster for Nurses : Disabled World.
From our Ebola Virus section - Full List (15 Items)

Submit disability news, coming events, as well as assistive technology product news and reviews.

Loan Information for low income singles, families, seniors and disabled. Includes home, vehicle and personal loans.

Famous People with Disabilities - Well known people with disabilities and conditions who contributed to society.

List of awareness ribbon colors and their meaning. Also see our calendar of awareness dates.

Blood Pressure Chart - What should your blood pressure be, and information on blood group types/compatibility.

1 : 20 New Episodes of Letters to Lynette with Dr. Lynette Louise to Air on The Autism Channel in 2018
2 : Turnstone Center Designated as Official Paralympic Training Site by US Olympic Committee
3 : Help Your Child in School by Adding Language to The Math
4 : 50% of Retirees Saw Little or No COLA Increase in Net 2018 Social Security Benefits
5 : Turnstone Endeavor Games Concludes with National Records Broken
6 : Spinning in Circles and Learning From Myself by Tsara Shelton
7 : St. Louis HELP Medical Equipment Donation Drive Generates Record-Breaking Results
8 : People Who Snore Suffer from Palate Nerve and Muscle Damage

*Press Release by NIH/National Institute of Allergy and Infectious Diseases: Disabled World makes no warranties or representations in connection therewith. If you are connected with this page and want it corrected/updated please contact us.

Disclaimer: This site does not employ and is not overseen by medical professionals. Content on Disabled World is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. See our Terms of Service for more information.

Reporting Errors: Disabled World is an independent website, your assistance in reporting outdated or inaccurate information is appreciated. If you find an error please let us know.

© 2004 - 2018 Disabled World™